A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Cao, Hui Hui ^a   Zheng, Chun Peng ^b   Wang, Shao Hong ^b   Wu, Jian Yi ^a   Shen, Jin Hui ^b   Xu, Xiu E ^a   Fu, Jun Hui ^b   Wu, Zhi Yong ^b   Li, En Min ^a   Xu, Li Yan ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FASCIN; TRANSCRIPTION FACTOR SP1; ACTIN BINDING PROTEIN; CARRIER PROTEIN; EGFR PROTEIN, HUMAN; SP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; OVERALL SURVIVAL; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SURVIVAL PREDICTION; CARCINOMA, SQUAMOUS CELL; CHINA; ESOPHAGEAL NEOPLASMS; GENETICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CHINA; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SP1 TRANSCRIPTION FACTOR; SURVIVAL RATE;

EID: 84929422979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106007     Document Type: Article

References (33)

1. Oesophageal cancer statistics website. Available: http://www. cancerresearchuk.org/cancer-info/cancerstats/types/oesophagus/. Updated: 2014 April 17.
2. Li LW, Li YY, Li XY, Zhang CP, Zhou Y, et al. (2011) A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma. BMC Cancer 11: 52-59.
3. Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, et al. (2010) A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 139: 1995-2004.
4. Benowitz S (2008) Revised guidelines signal that gene expression profiles are coming of age. J Natl Cancer Inst 100: 916-917.
5. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856. (Pubitemid 41746029)
6. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536. (Pubitemid 34130608)
7. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826. (Pubitemid 40051905)
8. Sveen A, Ågesen TH, Nesbakken A, Meling GI, Rognum TO, et al. (2012) ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients. Clin Cancer Res 18: 6001-6010.
9. Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P (2009) A Three-Gene Signature for Outcome in Soft Tissue Sarcoma. Clin Cancer Res 15: 5191-5198.
10. Lu XF, Li EM, Du ZP, Xie JJ, Guo ZY, et al. (2010) Specificity protein 1 regulates fascin expression in esophageal squamous cell carcinoma as the result of the epidermal growth factor/extracellular signal-regulated kinase signaling pathway activation. Cell Mol Life Sci 67: 3313-3329.
11. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4: S9-15.
12. Anonymous (2007) Targeting HER1/EGFR: Pathway to Progress in Cancer Therapy. Oncology (Williston Park) 21: 2 p preceding 1754.
13. Dutta PR, Maity A (2007) Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254: 165-177. (Pubitemid 47161103)
14. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, et al. (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 15-31.
15. Grothey A, Hashizume R, Sahin AA, McCrea PD (2000) Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 83: 870-873.
16. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, et al. (2005) Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 11: 2597-2605. (Pubitemid 40569459)
17. Zhao Q, Shen JH, Shen ZY, Wu ZY, Xu XE, et al. (2010) Phosphorylation of Fascin Decreases the Risk of Poor Survival in Patients With Esophageal Squamous Cell Carcinoma. J Histochem Cytochem 58: 979-988.
18. Sun LL, Sun XX, Xu XE, Zhu MX, Wu ZY, et al. (2013) Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma. Acta Histochem 115: 56-62.
19. Xu QX, Li EM, Zhang YF, Liao LD, Xu XE, et al. (2012) Overexpression of sigma1 receptor and its positive associations with pathologic TNM classification in esophageal squamous cell carcinoma. J Histochem Cytochem 60: 457-466.
20. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, et al. (2003) Current perspectives on HER2 testing: a review of National Testing Guidelines. Mod Pathol 16: 173-182. (Pubitemid 36245750)
21. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, et al. (2010) High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59: 953-962.
22. Kadara H, Behrens C, Yuan P, Solis L, Liu D, et al. (2011) A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis. Clin Cancer Res 17: 1490-1501.
23. Garcia I, Mayol G, Ríos J, Domenech G, Cheung NK, et al. (2012) A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clin Cancer Res 18: 2012-2023.
24. Gonzaga IM, Soares-Lima SC, de Santos PT, Blanco TC, et al. (2012) Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer 12: 569-579.
25. Zhang H, Xu L, Xiao D, Xie J, Zeng H, et al. (2006) Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma. J Clin Pathol 59: 958-964. (Pubitemid 44422851)
26. Krikelis D, Bobos M, Karayannopoulou G, Resiga L, Chrysafi S, et al. (2013) Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. BMC Clin Pathol 13: 1-15.
27. Zhu H, Bhaijee F, Ishaq N, Pepper DJ, Backus K, et al. (2013) Correlation of Notch1, pAKT and nuclear NF-kB expression in triple negative breast cancer. Am J Cancer Res 3: 230-239.
28. Gou HF, Li X, Qiu M, Cheng K, Li LH, et al. (2013) Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One 8: e62175-62181.
29. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A (2009) Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 35: 262-271.
30. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, et al. (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negativebreast cancer. J Clin Oncol 30: 2615-2623.
31. Chen Y, Wu X, Bu S, He C, Wang W, et al. (2012) Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci 103: 1979-1984.
32. Tan VY, Lewis SJ, Adams JC, Martin RM (2013) Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med 11: 52-68.
33. Chen L, Yang S, Jakoncic J, Zhang JJ, Huang XY (2010) Migrastatin analogues target fascin to block tumour metastasis. Nature 464: 1062-1066.